Targeted Therapy (Investigational Antibody / ADC)
48 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational Antibody / ADC) (48)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Ganitumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Ganitumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Ifinatamab Deruxtecan |
Anti-B7-H3 ADC, Topoisomerase I Inhibitor Payload | Solid Tumour | ||
|
Molecule
Ifinatamab Deruxtecan
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-B7-H3 ADC, Topoisomerase I Inhibitor Payload |
||||
Indatuximab Ravtansine |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Indatuximab Ravtansine
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Inebilizumab (Onc Adjacent) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Inebilizumab (Onc Adjacent)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Istiratumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Istiratumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Lumretuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Lumretuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Luveltamab Tazevibulin |
Anti-FOLR1 ADC, Hemiasterlin Payload | Solid Tumour | ||
|
Molecule
Luveltamab Tazevibulin
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-FOLR1 ADC, Hemiasterlin Payload |
||||
MEDI3617 (Anti-Ang2) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
MEDI3617 (Anti-Ang2)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Milatuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Milatuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Mirvetuximab (Ref) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Mirvetuximab (Ref)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Navicixizumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Navicixizumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Nimotuzumab (Head & Neck) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Nimotuzumab (Head & Neck)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
GanitumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Ifinatamab DeruxtecanTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-B7-H3 ADC, Topoisomerase I Inhibitor Payload |
|
Indatuximab RavtansineTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Inebilizumab (Onc Adjacent)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
IstiratumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
LumretuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Luveltamab TazevibulinTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-FOLR1 ADC, Hemiasterlin Payload |
|
MEDI3617 (Anti-Ang2)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
MilatuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Mirvetuximab (Ref)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
NavicixizumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Nimotuzumab (Head & Neck)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|